Information Provided By: 
Fly News Breaks for March 5, 2020
IONS
Mar 5, 2020 | 15:45 EDT
Cantor Fitzgerald analyst Eliana Merle believes the Phase 1 study suspension probably has limited read to the ongoing Phase 3 program. The infection serious adverse events were likely driven by the use of catheter injections, which are not used in the Phase 3 trial, in this exploratory biomarker study, Merle tells investors in a research note. Ionis and Roche (RHHBY) plan to restart the Phase I study, but reducing the time the catheter is in, adds the analyst. She keeps a Neutral rating on Ionis shares with a $65 price target.
News For IONS From the Last 2 Days
There are no results for your query IONS
